NEW YORK (GenomeWeb) – Molecular diagnostics firm Admera Health announced today that it has received approval from the New York State Clinical Laboratory Evaluation Program for its 50-gene PGxOne Plus pharmacogenomics test. 

PGxOne Plus uses next-generation sequencing technology to interrogate genes with the aim of predicting how patients will respond to drug therapy in cardiology, psychiatry, pain management, and oncology, among other areas. Reports sent to clinicians include information on whether specific drugs should be avoided, alternative treatments, and dosage adjustments.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

Sep
18
Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.